AI assistant
Clene Inc. — Director's Dealing 2021
Apr 13, 2021
34487_dirs_2021-04-13_d5726ca6-126a-4a5b-bc56-d8ef1ad0c682.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3/A — Form 3/A
Issuer: Clene Inc. (CLNN)
CIK: 0001822791
Period of Report: 2020-12-30
Reporting Person: Etherington Robert Dee (N/A)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Options (Right to buy) | $0.53 | Common Stock (428674.00) | Direct | ||
| Stock Options (Right to buy) | $0.15 | Common Stock (1092777.00) | Direct |
Footnotes
F1: This Form 3 amendment is being filed to correct an error in the original Form 3 filed on January 4, 2021 and subsequently amended on January 7, 2021 to reflect a correction in the exercise price that resulted from an internal calculation error.
F2: Awarded under the Clene Nanomedicine, Inc. 2014 Stock Plan on November 23, 2015 and currently exercisable. The options expire 10 years from the date of the grant.
F3: Awarded under the Clene Nanomedicine, Inc. 2014 Stock Plan on July 31, 2014 and currently exercisable. The options expire 10 years from the date of the grant.